Evidence map›Paper›PMID 40530895›Full record

ArticleACS chemical biology2025

High-Throughput Screening of Potent Drug-like Molecules Targeting 17β-HSD10 for the Treatment of Alzheimer's Disease and Cancer.

Laura Aitken, Gemma Baillie, Andrew Pannifer, Angus Morrison, Louise L Major, Magnus S Alphey, Ritika Sethi, Martin Timmerman, John Robinson, Jennifer Riley and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Laura AitkenUniversity of St. Andrews School of Chemistry, Biomolecular Sciences Building, North Haugh, St. Andrews KY16 9TF, U.K.
Gemma BaillieBioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, U.K.
Andrew PanniferExcientia, Oxford Science Park, The Schrödinger Building, Oxford OX4 4GE, U.K.ORCID 0000-0003-0866-308X
Angus MorrisonBioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, U.K.
Louise L MajorBiomedical Science Research Complex, University of St. Andrews School of Biology, North Haugh, St. Andrews KY16 9ST, U.K.
Magnus S AlpheyBiomedical Science Research Complex, University of St. Andrews School of Biology, North Haugh, St. Andrews KY16 9ST, U.K.
Ritika SethiGlaxo Smith Kline Biologicals, rue de l'Institut 89, 1330 Rixensart, Belgium.
Martin TimmermanEuropean Lead Factory, Pivot Park-Banting Building (RE600), Kloosterstraat 9, 5349 AB Oss, The Netherlands.
John RobinsonBioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, U.K.
Jennifer RileyWellcome Centre of Anti-infectives Research, Drug Discovery Unit, University of Dundee School of Life Sciences, Dow Street, Dundee DD1 5EH, U.K.
Yoko ShishikuraWellcome Centre of Anti-infectives Research, Drug Discovery Unit, University of Dundee School of Life Sciences, Dow Street, Dundee DD1 5EH, U.K.
Lizbe KoekemoerUniversity of Oxford Centre for Medicines Discovery, Old Road Campus Research Building, Oxford OX3 7FZ, U.K.
Frank Von DelftUniversity of Oxford Centre for Medicines Discovery, Old Road Campus Research Building, Oxford OX3 7FZ, U.K.ORCID 0000-0003-0378-0017
Helma RutjesEuropean Lead Factory, Pivot Park-Banting Building (RE600), Kloosterstraat 9, 5349 AB Oss, The Netherlands.
Kevin D ReadWellcome Centre of Anti-infectives Research, Drug Discovery Unit, University of Dundee School of Life Sciences, Dow Street, Dundee DD1 5EH, U.K.ORCID 0000-0002-8536-0130
Philip S JonesBioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, U.K.
Stuart P McElroyBioAscent Discovery Ltd, Bo'Ness Road, Newhouse, Lanarkshire ML1 5UH, U.K.
Terry K SmithUniversity of St. Andrews School of Chemistry, Biomolecular Sciences Building, North Haugh, St. Andrews KY16 9TF, U.K.ORCID 0000-0003-1994-2009
Frank J Gunn-MooreBiomedical Science Research Complex, University of St. Andrews School of Biology, North Haugh, St. Andrews KY16 9ST, U.K.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, the first industrial-scale high-throughput screening of nearly 350,000 drug-like molecules targeting the enzyme 17β-HSD10, a promising therapeutic target for Alzheimer's disease and cancers, is presented. Two novel series of potent 17β-HSD10 inhibitors that demonstrate low nanomolar potency against both the enzyme and

Indexed as

17-Hydroxysteroid DehydrogenasesAlzheimer DiseaseAntineoplastic AgentsEnzyme InhibitorsHigh-Throughput Screening AssaysNeoplasms3-Hydroxyacyl CoA DehydrogenasesAnimalsCell Line, TumorHumansMice17-Hydroxysteroid Dehydrogenases3-Hydroxyacyl CoA DehydrogenasesAntineoplastic AgentsEnzyme InhibitorsHSD17B10 protein, human

Identifiers

PMID40530895
PMCPMC12281485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.